UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models

British journal of cancer, 2014-04, Vol.110 (7), p.1733-1743

2014

Volltextzugriff (PDF)

Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview

Journal of clinical oncology, 2001-03, Vol.19 (5), p.1501-1518

2001

Volltextzugriff (PDF)

Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer : Role of drug sequence and dose

Cancer research (Chicago, Ill.), 2000-07, Vol.60 (14), p.3717-3721

2000

Volltextzugriff (PDF)

Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors

Journal of clinical oncology, 1997-01, Vol.15 (1), p.389-400

1997

Volltextzugriff (PDF)

Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study

Annals of oncology, 2003-09, Vol.14 (9), p.1442-1448

2003

Volltextzugriff (PDF)

Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1α expression, resulting in reduced angiogenesis

Oncogene, 2006-04, Vol.25 (17), p.2509-2519

2006

Volltextzugriff (PDF)

Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)

Annals of oncology, 1997-12, Vol.8 (12), p.1221-1228

1997

Volltextzugriff (PDF)

Modeling of the time-dependency of in vitro drug cytotoxicity and resistance

Cancer research (Chicago, Ill.), 1998-12, Vol.58 (24), p.5749-5761

1998

Volltextzugriff (PDF)

MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors

The American journal of pathology, 1996-09, Vol.149 (3), p.853-858

1996

Volltextzugriff (PDF)

Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer

European Journal of Cancer, 1998-02, Vol.34 (3), p.296-306

1998

Volltextzugriff (PDF)

Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer

Journal of clinical oncology, 1999-03, Vol.17 (3), p.907-913

1999

Volltextzugriff (PDF)

d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors

Clinical cancer research, 1996-12, Vol.2 (12), p.1961-1968

1996

Volltextzugriff (PDF)

S-phase modulation by irinotecan : pilot studies in advanced solid tumors

Cancer chemotherapy and pharmacology, 2005-11, Vol.56 (5), p.447-454

2005

Volltextzugriff (PDF)

5-Ethynyluracil (776C85) : modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma

Cancer research (Chicago, Ill.), 1994-03, Vol.54 (6), p.1507-1510

1994

Volltextzugriff (PDF)

Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model

Cancer research (Chicago, Ill.), 1998-08, Vol.58 (15), p.3270-3274

1998

Volltextzugriff (PDF)

Overexpression of Bax Enhances Antitumor Activity of Chemotherapeutic Agents in Human Head and Neck Squamous Cell Carcinoma

Clinical cancer research, 2000-02, Vol.6 (2), p.718-724

2000

Volltextzugriff (PDF)

Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines

British journal of cancer, 1999-12, Vol.81 (8), p.1304-1310

1999

Volltextzugriff (PDF)

Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis

Anticancer research, 1998-09, Vol.18 (5A), p.3499

1998

Volltextzugriff (PDF)

PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein

Clinical cancer research, 1996-02, Vol.2 (2), p.369-377

1996

Volltextzugriff (PDF)

P-glycoprotein in human sarcoma: evidence for multidrug resistance

Journal of clinical oncology, 1987-09, Vol.5 (9), p.1452-1460

1987

Volltextzugriff (PDF)

DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells

Cancer research (Chicago, Ill.), 1996-10, Vol.56 (20), p.4715-4723

1996

Volltextzugriff (PDF)

Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer

Cancer research (Chicago, Ill.), 1998-04, Vol.58 (8), p.1695-1699

1998

Volltextzugriff (PDF)

New drugs in therapy of colorectal cancer: preclinical studies

Seminars in oncology, 1999-12, Vol.26 (6), p.612

1999

Volltextzugriff (PDF)

Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications

European journal of cancer (1990), 1999-06, Vol.35 (6), p.984-993

1999

Volltextzugriff (PDF)

Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents

Seminars in oncology, 1998-10, Vol.25 (5), p.584

1998

Volltextzugriff (PDF)

1 – 25 von 390

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(349)
Mit Volltextzugriff
(291)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(216)
Life Sciences & Biomedicine
(211)
Humans
(202)
Oncology
(156)
Biological And Medical Sciences
(124)
Female
(122)
Medical Sciences
(118)
Animals
(102)
Pharmacology. Drug Treatments
(95)
Antineoplastic Agents
(89)
Mice
(61)
Middle Aged
(53)
Chemotherapy
(49)
Tumor Cells, Cultured
(47)
Adult
(45)
Hematology, Oncology And Palliative Medicine
(45)
Aged
(44)
Fluorouracil - Administration & Dosage
(44)
Male
(44)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(42)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models

Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview

Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer : Role of drug sequence and dose

Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors

Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study

Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1α expression, resulting in reduced angiogenesis

Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)

Modeling of the time-dependency of in vitro drug cytotoxicity and resistance

MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors

Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer

Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer

d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors

S-phase modulation by irinotecan : pilot studies in advanced solid tumors

5-Ethynyluracil (776C85) : modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma

Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model

Overexpression of Bax Enhances Antitumor Activity of Chemotherapeutic Agents in Human Head and Neck Squamous Cell Carcinoma

Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines

Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis

PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein

P-glycoprotein in human sarcoma: evidence for multidrug resistance

DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells

Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer

New drugs in therapy of colorectal cancer: preclinical studies

Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications

Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents

Suchergebnisse filtern